Alcon: Conjunctivitis trials

The registry lists 29 Conjunctivitis studies with Alcon as lead sponsor. 0 are open to participants now and 15 have results posted.

Phase 1 1Phase 2 5Phase 3 11Phase 4 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese SubjectsCompletedNCT02322216Phase 3Results posted
• Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in JapanCompletedNCT02251613Phase 4Results posted
• Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic ConjunctivitisCompletedNCT02079649Phase 2Results posted
• Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedNCT01743027Phase 3Results posted
• A Six-Week Safety Study of an Investigational Ophthalmic SolutionCompletedNCT01698814Phase 3Results posted
• Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis PatientsCompletedNCT01697969Phase 4Results posted
• An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese PatientsCompletedNCT01573910Phase 3Results posted
• Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) ModelCompletedNCT01479374Phase 3Results posted
• Assessment of Alcon's Ocular Image Quantification SystemCompletedNCT01282138Phase 4Results posted
• Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic ConjunctivitisCompletedNCT01159769Phase 4Results posted
• Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic ConjunctivitisCompletedNCT01119287Phase 4Results posted
• Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)CompletedNCT00818805Phase 4Results posted
• Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic TreatmentCompletedNCT00798577Phase 4Results posted
• Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial ConjunctivitisCompletedNCT00759148Phase 3Results posted
• Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial FloraCompletedNCT00312338Phase 4Results posted
• Safety and Comfort of AL-4943A Ophthalmic SolutionCompletedNCT01326858Phase 1
• Patient Perception Study for AL-4943ACompletedNCT01294969Phase 4
• A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic ConjunctivitisCompletedNCT01272089Phase 4
• Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial ConjunctivitisWithdrawnNCT01238783Phase 2
• Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric PatientsCompletedNCT01109485Phase 4
• An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic ConjunctivitisCompletedNCT01037179Phase 3
• AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated InflammationCompletedNCT01001091Phase 2
• Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese SubjectsCompletedNCT00987272Phase 3
• An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral ConjunctivitisTerminatedNCT00901693Phase 2
• To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen ChallengeWithdrawnNCT00881673Phase 2
• Mast-Cell Stabilizing Effects of OlopatadineCompletedNCT00389025Phase 4
• AL-15469A for the Treatment of Bacterial ConjunctivitisCompletedNCT00332293Phase 3
• AL-15469A for the Treatment of Bacterial ConjunctivitisCompletedNCT00331916Phase 3
• Olopatadine 0.2% for the Treatment of Allergic ConjunctivitisCompletedNCT00331500Phase 3